A Galindo-Tovar1, A J Kaumann. 1. Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
Abstract
BACKGROUND AND PURPOSE: beta(1) and beta(2)-adrenoceptors coexist in murine heart but beta(2)-adrenoceptor-mediated effects have not been detected in atrial and ventricular tissues, possibly due to marked phosphodiesterase (PDE) activity. We investigated the influence of the PDE3 inhibitor cilostamide and PDE4 inhibitor rolipram on the effects of (-)-adrenaline in three regions of murine heart. EXPERIMENTAL APPROACH: (-)-Adrenaline-evoked cardiostimulation was compared on sinoatrial beating rate, left atrial and right ventricular contractile force in isolated tissues from 129SvxC57B1/6 cross mice. Ventricular arrhythmic contractions were also assessed. KEY RESULTS: Both rolipram (1 microM) and cilostamide (300 nM) caused transient sinoatrial tachycardia but neither enhanced the chronotropic potency of (-)-adrenaline. Rolipram potentiated 19-fold (left atrium) and 7-fold (right ventricle) the inotropic effects of (-)-adrenaline. (-)-Adrenaline elicited concentration-dependent ventricular arrhythmias that were potentiated by rolipram. All effects of (-)-adrenaline were antagonized by the beta(1)-adrenoceptor-selective antagonist CGP20712A (300 nM). Cilostamide (300 nM) did not increase the chronotropic and inotropic potencies of (-)-adrenaline, but administered jointly with rolipram in the presence of CGP20712A, uncovered left atrial inotropic effects of (-)-adrenaline that were prevented by the beta(2)-adrenoceptor-selective antagonist ICI118551. CONCLUSIONS AND IMPLICATIONS: PDE4 blunts the beta(1)-adrenoceptor-mediated effects of (-)-adrenaline in left atrium and right ventricle but not in sinoatrial node. Both PDE3 and PDE4 reduce basal sinoatrial rate in a compartment distinct from the beta(1)-adrenoceptor compartment. PDE3 and PDE4, acting in concert, prevent left atrial beta(2)-adrenoceptor-mediated inotropy. PDE4 partially protects the right ventricle against (-)-adrenaline-evoked arrhythmias.
BACKGROUND AND PURPOSE: beta(1) and beta(2)-adrenoceptors coexist in murine heart but beta(2)-adrenoceptor-mediated effects have not been detected in atrial and ventricular tissues, possibly due to marked phosphodiesterase (PDE) activity. We investigated the influence of the PDE3 inhibitor cilostamide and PDE4 inhibitor rolipram on the effects of (-)-adrenaline in three regions of murine heart. EXPERIMENTAL APPROACH: (-)-Adrenaline-evoked cardiostimulation was compared on sinoatrial beating rate, left atrial and right ventricular contractile force in isolated tissues from 129SvxC57B1/6 cross mice. Ventricular arrhythmic contractions were also assessed. KEY RESULTS: Both rolipram (1 microM) and cilostamide (300 nM) caused transient sinoatrial tachycardia but neither enhanced the chronotropic potency of (-)-adrenaline. Rolipram potentiated 19-fold (left atrium) and 7-fold (right ventricle) the inotropic effects of (-)-adrenaline. (-)-Adrenaline elicited concentration-dependent ventricular arrhythmias that were potentiated by rolipram. All effects of (-)-adrenaline were antagonized by the beta(1)-adrenoceptor-selective antagonist CGP20712A (300 nM). Cilostamide (300 nM) did not increase the chronotropic and inotropic potencies of (-)-adrenaline, but administered jointly with rolipram in the presence of CGP20712A, uncovered left atrial inotropic effects of (-)-adrenaline that were prevented by the beta(2)-adrenoceptor-selective antagonist ICI118551. CONCLUSIONS AND IMPLICATIONS: PDE4 blunts the beta(1)-adrenoceptor-mediated effects of (-)-adrenaline in left atrium and right ventricle but not in sinoatrial node. Both PDE3 and PDE4 reduce basal sinoatrial rate in a compartment distinct from the beta(1)-adrenoceptor compartment. PDE3 and PDE4, acting in concert, prevent left atrial beta(2)-adrenoceptor-mediated inotropy. PDE4 partially protects the right ventricle against (-)-adrenaline-evoked arrhythmias.
Authors: P J Laitinen; K M Brown; K Piippo; H Swan; J M Devaney; B Brahmbhatt; E A Donarum; M Marino; N Tiso; M Viitasalo; L Toivonen; D A Stephan; K Kontula Journal: Circulation Date: 2001-01-30 Impact factor: 29.690
Authors: Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; John A Vest; Anetta Wronska; Andrew R Marks Journal: Proc Natl Acad Sci U S A Date: 2006-01-06 Impact factor: 11.205
Authors: Simon J MacKenzie; George S Baillie; Ian McPhee; Carolynn MacKenzie; Rachael Seamons; Theresa McSorley; Jenni Millen; Matthew B Beard; Gino van Heeke; Miles D Houslay Journal: Br J Pharmacol Date: 2002-06 Impact factor: 8.739
Authors: Jürgen F Heubach; Marianne Blaschke; Sian E Harding; Ursula Ravens; Alberto J Kaumann Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2003-03-04 Impact factor: 3.000
Authors: Faraz Afzal; Jan Magnus Aronsen; Lise Román Moltzau; Ivar Sjaastad; Finn Olav Levy; Tor Skomedal; Jan-Bjørn Osnes; Eirik Qvigstad Journal: Br J Pharmacol Date: 2011-01 Impact factor: 8.739
Authors: Peter Molenaar; Torsten Christ; Rizwan I Hussain; Andreas Engel; Emanuel Berk; Katherine T Gillette; Lu Chen; Alejandro Galindo-Tovar; Kurt A Krobert; Ursula Ravens; Finn Olav Levy; Alberto J Kaumann Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739
Authors: F Afzal; K W Andressen; H K Mørk; J M Aronsen; I Sjaastad; C P Dahl; T Skomedal; F O Levy; J-B Osnes; E Qvigstad Journal: Br J Pharmacol Date: 2008-09-01 Impact factor: 8.739
Authors: G Simonis; T Christ; S K Bährle; M Pena; S P Schoen; R Marquetant; U Ravens; R H Strasser Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-06-10 Impact factor: 3.000